Avidity Biosciences Q2 EPS $(0.66) Beats $(0.80) Estimate, Sales $2.32M Beat $2.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences reported Q2 earnings per share (EPS) of $(0.66), beating the analyst consensus estimate of $(0.80) by 17.5%. This is a 28.26% increase over losses from the same period last year. The company also reported quarterly sales of $2.32 million, beating the analyst consensus estimate of $2.14 million by 8.22%. This is a 6.34% increase over sales from the same period last year.
August 08, 2023 | 10:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences reported better than expected Q2 earnings and sales, which could positively impact the stock in the short term.
Avidity Biosciences reported better than expected Q2 earnings and sales. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100